๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Considerations for treating dyslipidemia in special diabetic populations

โœ Scribed by Anne Peters Harmel

Book ID
102154311
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
84 KB
Volume
18
Category
Article
ISSN
1520-7552

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

This is a review of the problem of dyslipidemia and cardiovascular disease (CVD) in special diabetic populations. Clearly all patients with diabetes are at increased risk for CVD compared to nonโ€diabetic populations. But within the subset that is patients with diabetes there are individuals who are particularly vulnerable. These groups include women, who are often overlooked and undertreated for their cardiovascular risk. Additionally, it includes those with fewer resources, many from minority populations, who are at very high risk for poor preventive care and serious cardiovascular morbidity. This review details the risk for CVD in a variety of different diabetic highโ€risk groups. It then discusses treatment options and approaches that should be employed in these populations. Copyright ยฉ 2002 John Wiley & Sons, Ltd.

๐Ÿ“œ SIMILAR VOLUMES

Crisis Model for Older Adults: Special C
Crisis Model for Older Adults: Special Considerations for an Aging Population
โœ Christin M. Jungers; Leslie Slagel ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› American Counseling Association ๐ŸŒ English โš– 150 KB

The authors propose a new crisis intervention model that accounts for the needs of older adults in crisis by giving special attention to the roles of advocacy, education, and prevention.

Pravastatin compared to bezafibrate in t
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus
โœ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 99 KB ๐Ÿ‘ 2 views

Background Both HMG-CoA reductase inhibitors and ยฎbric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg bezaยฎbrate, a ยฎbric acid deriva